Trial · NCT02437383
Outcomes35
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 35
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in the Weekly Mean Pain Index After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the Weekly Mean Pain Intensity After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the Weekly Mean Pain Duration After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | units on a scale | LEAST_SQUARES_MEAN | |
| SECONDARY | Change in the SF-McGill Pain Questionnaire Affective Component After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the SF-McGill Pain Questionnaire Sensory Component After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the SF-McGill Pain Questionnaire Present Facial Pain Intensity After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Intensity After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Duration After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the SF-McGill Pain Questionnaire Weekly Fatigue After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants Stratified Per Graded Chronic Pain Scale (GCPS) Grade After 9 Weeks of Treatment | Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in the Jaw Functional Limitation Scale (JFLS) Global Score After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the Headache Impact Test (HIT-6) Global Score After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the Pittsburgh Sleep Quality Index (PSQI) Global Score After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants Stratified Per Dichotomized Score From the Patient Global Impression of Change (PGIC) Scale After 9 Weeks of Treatment | Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in the Perceived Stress Scale (PSS) Global Score After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the Hospital Anxiety and Depression Scale (HADS) Depression Score After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Score After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the Symptom Checklist 90-Revised (SCL-90R) Somatization Scale Score After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the SF-12 Health Survey v2 (SF-12v2) Physical Component Summary (PCS) After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in the SF-12 Health Survey v2 (SF-12v2) Mental Component Summary (MCS) After 9 Weeks of Treatment | Visit 1 (study day 0) and Visit 4 (study day 63 +/-7) | All participants who received at least one dose of study medication and provided at least one post-baseline outcome measure. | score on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02437383/outcomes